Panthera On The SMO Model, Responsible Growth Priorities And The Hybridized Trial Of The Future
Executive Summary
In this episode of the In Vivo podcast, Jo Shorthouse speaks with the co-founder and chief commercial officer of the site management organization, Panthera Biopartners. The discussion centers on the practicalities and reality of running clinical trial sites as a business, and the age-old challenge of patient recruitment.
With recommendations coming from the EU this past December on decentralized clinical trials, the clinical research industry is still attempting to find global harmonization that would lead trial modernization.
Many clinical trials cannot, for logistical reasons, be fully decentralized, that is the view of Panthera Biopartners’ Ian Smith and Chris Dodd, who talk with In Vivo about the decentralized and hybridized trial model, and where efficiencies can be found along the clinical trial pathway.
Also up for discussion is the efficiencies found with the SMO model, and how the firm is funding its future responsibly.
Time stamps:
1:45 The Panthera Model
5:15 The SMO Approach To Study Set Up
14:00 A Data Approach To Patient Recruitment And Retention
18: 46 Decentralized Trials
21:20 The hybridized trial model
25:45 Growth priorities and moving to a tactical partnership model
27:00 Responsible growth